Dawn Maze

Assistant Professor

University of Toronto

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dawn Maze is an Assistant Professor at the University of Toronto, Canada. Her research focuses on hematologic malignancies, particularly in the areas of acute lymphoblastic leukemia and acute myeloid leukemia. Recent articles explore treatment outcomes, safety of therapeutic regimens, and the impact of genetic mutations on patient outcomes.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Dennis Dong Hwan Kim

CANADA

View details

Vikas Gupta

CANADA

View details

Dina Khalaf

Associate Professor

UNITED STATES

View details

Hassan Sibai

CANADA

View details

Yuliang Shi

Teaching and Research Assistant

University of Waterloo

CANADA

View details

Daniel Xia

CANADA

View details

Adam Smith

Assistant Professor

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dawn Maze

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

Correction to: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study (Bone Marrow Transplantation, (2024), 59, 2, (196-202), 10.1038/s41409-023-02146-6)

Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms

Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase

Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms

Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen

Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia

Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor

Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis

Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR-ABL negative myeloproliferative neoplasms

A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia

Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort

Osteolytic lesion in polycythemia vera: First report and review of literature

Collaborators (7)

Dennis Dong Hwan Kim

Vikas Gupta

Dina Khalaf

Hassan Sibai

Yuliang Shi

Daniel Xia

Adam Smith

Make your next move.